Inhibition of atherosclerosis progression, intimal hyperplasia, and oxidative stress by simvastatin and ivabradine may reduce thoracic aorta's stiffness in hypercholesterolemic rabbits

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 4, 2016, Pages 412-422

  Koniari, Ioanna ^a   Mavrilas, Dimosthenis ^b   Apostolakis, Efstratios ^c   Papadimitriou, Evangelia ^b   Papadaki, Helen ^b   Papalois, Apostolos ^d   Poimenidi, Evangelia ^b   Xanthopoulou, Ioanna ^a   Hahalis, George ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d ELPEN Pharmaceuticals   (Greece)

Author keywords

Arterial stiffness; Atherosclerosis; Ivabradine; Oxidative stress; Simvastatin

Indexed keywords

3 NITROTYROSINE; IVABRADINE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; ANTIOXIDANT; BENZAZEPINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY COMPLIANCE; ARTICLE; ATHEROGENIC DIET; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; DESCENDING AORTA; DISEASE COURSE; DRUG MECHANISM; FOAM CELL; HEART RATE; HYPERCHOLESTEROLEMIA; HYPERPLASIA; IMAGE ANALYSIS; IMMUNOREACTIVITY; INTIMAL HYPERPLASIA; LIPID BLOOD LEVEL; MALE; NEOINTIMA; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; AORTIC DISEASES; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DISEASE MODEL; DRUG EFFECTS; LEPORIDAE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; THORACIC AORTA;

ANIMALS; ANTIOXIDANTS; AORTA, THORACIC; AORTIC DISEASES; ATHEROSCLEROSIS; BENZAZEPINES; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERPLASIA; MALE; NEOINTIMA; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RABBITS; SIMVASTATIN; VASCULAR STIFFNESS;

EID: 84978900517     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415617289     Document Type: Article

References (49)

1. Robinson J, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol. 2014; 63(25 pt A):2779-2785. doi:10.1016/j.jacc.2014.04.009.
2. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55(13):1318-1327. doi:10.1016/j.jacc.2009.10.061.
3. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932-943. doi:10.1161/01.ATV.00001 60548.78317.29.
4. McEniery CM, Cockcroft JR. Does arterial stiffness predict atherosclerotic coronary events? Adv Cardiol. 2007;44:160-172. doi: 10.1159/000096728.
5. Umeji K, Umemoto S, Itoh S, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2006;(5)291:h2522-h2532. doi:10.1152/ajpheart.01198.2005.
6. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003;91(4a):4b-8b. http://dx.doi.org/10.1016/S0002-9149(02)03267-8.
7. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol. 2002;13(6):1673-1681. doi:10.1097/01.ASN.0000018 400.39687.8C.
8. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C, et al. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J Hypertens. 2002;20(3):429-437. doi:10.1097/00004872-200203000-00018.
9. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013;26(5):608-616. doi:10.1093/ajh/hps098.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;19(8934):1383-1389. doi:10.1016/S0140-6736(94) 90566-5.
11. Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;6(9326):23-33. doi:10.1016/S0140-6736(02)09328-5.
12. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117(18):2377-2387. doi: 10.1161/CIRCULATIONAHA.107.746537.
13. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996;14(7):897-901. doi:10.1097/00004872-199607000-00013.
14. Custodis F, Fries P, Müller A, et al. Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. J Vasc Res. 2012;49(5):432-440. doi:10.1159/000339547.
15. Koniari I, Mavrilas D, Papadaki H, et al. Structural and biomechanical alterations in rabbit thoracic aortas are associated with the progression of atherosclerosis. Lipids Health Dis. 2011;10:125. doi:10.1186/1476-511X-10-125.
16. Arora R, Hare DL, Zulli A. Simvastatin reduces endothelial NOS: caveolin-1 ratio but not the phosphorylation status of eNOS in vivo. J Atheroscler Thromb. 2012;19(8):705-711.
17. Giannarelli C1, Cimmino G, Connolly TM, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Vascul Pharmacol. 2010;52(1-2):77-83.
18. Peterson LH, Jensen RE, Parnell R. Mechanical properties of arteries in vivo. Circ Res. 1960;8:622-639. doi:10.1161/01.RES. 8.3.622.
19. Mikroulis D, Mavrilas D, Kapolos J, Koutsoukos PG, Lolas C. Physicochemical and microscopical study of calcific deposits from natural and bioprosthetic heart valves. Comparison and implications for mineralization mechanism. J Mater Sci Mater Med. 2002;13(9):885-889.
20. Hayashi K, Ide K, Matsumoto T. Aortic walls in atherosclerotic rabbits-mechanical study. J Biomech Eng. 1994;116(3):284-293. doi:10.1115/1.2895732.
21. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374. doi:10.1161/01. CIR.92.5.1355.
22. Koniari I, Apostolakis E, Diamantopoulos A, et al. Transauricular balloon angioplasty in rabbit thoracic aorta: a novel model of experimental restenosis. Lipids Health Dis. 2014;13:33. doi:10. 1186/1476-511X-13-33.
23. Papadopulos F, SpinelliM, Valente S, et al. Common tasks in microscopic and ultrastructural image analysis using Image J. Ultrastruct Pathol. 2007;31(6):401-407. doi:10.1080/01913120701719189.
24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307. doi:10.1056/NEJM199511163332001.
25. Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis. 2013;227(2):367-372. doi:10. 1016/j.atherosclerosis.2013.01.015.
26. Fukumoto, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103(7):993-999. doi:10.1161/01.CIR.103.7.993.
27. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33(5):1294-1304. doi:10.1016/S0735-1097(99)00018-2.
28. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens. 2002; 16(10):705-710. doi:10.1038/sj.jhh.1001470.
29. Hongo M, Tsutsui H, Mawatari E, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J. 2008;72(5): 722-728. http://dx.doi.org/10.1253/circj.72.722.
30. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009;54(4):763-768. doi:10.1161/HYPERTENSIONAHA. 109.138248.
31. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des. 2009; 15(3):290-303. doi:10.2174/138161209787354221.
32. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2002;17(8):1513-1517. doi:10.1093/ndt/17.8. 1513.
33. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Longterm effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19(2):103-109. doi:10. 1038/sj.jhh.1001786.
34. Lunder M, Janic M, Habjan S, Sabovic M. Subtherapeutic, lowdose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males-a pilot study. Atherosclerosis. 2011;215(2):446-451. doi:10.1016/j. atherosclerosis.2010.12.041.
35. Han SH, Kang EW, Yoon SJ, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2011;26(11):3722-3728. doi:10.1093/ndt/gfr108.
36. Pirro M, Schillaci G, Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2007;17(6):436-441. doi:http://dx.doi.org/10.1016/j.numecd.2006.02.009.
37. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis. 2001;155(1):245-250. doi:http://dx.doi.org/10.1016/S0021-9150 (00)00558-X.
38. Tam LS, Li EK, Shang Q, et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol. 2011; 40(6):411-421. doi:10.3109/03009742.2011.586649.
39. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39(6): 1020-1025. doi:10.1016/S0735-1097(02)01717-5.
40. Briones AM, Rodriguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension. 2009;54(1):142-149. doi:10.1161/HYPERTENSIONAHA.109.133710.
41. Xue L, Xu WH, Xu JZ, Zhang T, Bi HY, Shen BZ. Effect of cholesterol lowering on stiffness of aortic and femoral arterial walls in rabbits on a high fat diet. Chin Med J. 2009;122(12): 1444-1448. doi:10.3760/cma.j.issn.0366-6999.2009.12.017.
42. Tsirmoula S, Lamprou M, Hatziapostolou M, Kieffer N, Papadimitriou E. Pleiotrophin-induced endothelial cell migration is regulated by xanthine oxidase-mediated generation of reactive oxygen species. Microvasc Res. 2015;98:74-81. doi:10.1016/j. mvr.2015.01.001.
43. Hayashi T, Rani P JA, Fukatsu A, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004;176(2):255-263. doi:http://dx.doi.org/10.1016/j.athero sclerosis.2003.12.034.
44. Baumhäkel M, Custodis F, Schlimmer N, Laufs U, Böhm M. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis. 2010;212(1):55-62. doi: 10.1016/j.atherosclerosis.2010.03.002.
45. Kröller-Schön S, Schulz E,Wenzel P, et al. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. Basic Res Cardiol. 2010;106(6): 1147-1158. doi:10.1007/s00395-011-0227-3.
46. Dominguez-Rodriguez A, Blanco-Palacios G, Abreu-Gonzalez P. Increased heart rate and atherosclerosis: potential implications of ivabradine therapy. World J Cardiol. 2011;3(4):101-104. doi:10. 4330/wjc.v3.i4.101.
47. Bolduc V, Drouin A, Gillis MA, et al. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol. 2011;301(5):h2081-h2092. doi:10.1152/ajpheart.00706. 2011.
48. Albaladejo P, Carusi A, Apartian A, Lacolley P, Safar ME, Benetos A. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res. 2003;40(4):320-328. doi:10.1159/000072696.
49. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001;161(22):2685-2692.